Story

BofA Lifts Obesity Drug Market Forecast to $125 Billion on Eli Lilly's Global Strength

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
BofA Lifts Obesity Drug Market Forecast to $125 Billion on Eli Lilly's Global Strength
Text size
Background

Bank of America has raised its forecast for the global obesity drug market to $125 billion by 2036, citing robust international growth from Eli Lilly (NYSE:LLY) and stronger-than-expected pricing for GLP-1 therapies in the United States. The firm maintained its Buy rating on Lilly's stock in its analyst note.

Upgraded Forecast Cites Market Momentum

BofA analysts increased their market projection from a previous estimate of $114 billion, attributing the change to strong first-half results from key players Eli Lilly and Novo Nordisk. The new model incorporates higher international sales for tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound, and more resilient U.S. pricing.

The updated forecast also accounts for the addition of non-incretin alternatives to the market model, reflecting expectations for an expanding treatment landscape for weight-loss therapies.

International Growth and Pricing Power

Eli Lilly's international performance was a key driver for the revised outlook. According to the BofA report, the company's Mounjaro brand demonstrated significant global traction, with launches now spanning 40 core markets.

Key performance metrics highlighted by the bank include:

Sample IUX Markets – In-articleAd
  • International Mounjaro revenue growth of 174% year-over-year.
  • Sales outside the U.S. beating consensus expectations by 14%.
  • Average U.S. net revenue per injectable prescription holding at $580, down only 1% quarter-over-quarter.

Reflecting this pricing strength, BofA raised its fiscal 2026 estimate for Zepbound's blended price to $525 per prescription, a substantial increase from its prior estimate of $405.

Long-Term Outlook and Competition

Bank of America projects that international sales will constitute 42% of Lilly's global sales in the near term, growing to 46% by 2036. This underscores the importance of global expansion for market leaders.

While generic versions of semaglutide have become available in markets like India, Canada, and Brazil, BofA does not model them as a major disruptor in the 2026-2036 period. The report cited Lilly's experience in India, where Mounjaro volume grew without price cuts, suggesting market segmentation between branded and generic therapies. The firm also noted Lilly's pipeline, including the planned 2027 launch of retatrutide, as supportive of long-term growth.

Read next

More on Stocks
Back to latest news

LATEST